Trial
NCT00082225
LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Baylor College of Medicine
Collaborators
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor College of Medicine
Condition
Lymphoma
Intervention
CD45 antibodies
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-07